Preclinical optimization of Ly6E-targeted ADCs for increased durability and efficacy of anti-tumor response.
Dela Cruz Chuh J, Go M, Chen Y, Guo J, Rafidi H, Mandikian D, Sun Y, Lin Z, Schneider K, Zhang P, Vij R, Sharpnack D, Chan P, de la Cruz C, Sadowsky J, Seshasayee D, Koerber JT, Pillow TH, Phillips GD, Rowntree RK, Boswell CA, Kozak KR, Polson AG, Polakis P, Yu SF, Dragovich PS, Agard NJ.
Dela Cruz Chuh J, et al. Among authors: rafidi h.
MAbs. 2021 Jan-Dec;13(1):1862452. doi: 10.1080/19420862.2020.1862452.
MAbs. 2021.
PMID: 33382956
Free PMC article.